公司近期活动 - 公司管理层（首席执行官Joe Ciaffoni和首席财务官Ryan Preblick）将参加2025年11月13日在纽约市举行的Stifel 2025医疗健康大会，并主持一对一/小组会议及一场炉边谈话 [1] - 炉边谈话将于2025年11月13日美国东部时间上午8:40进行，并将通过公开网络直播对外提供 [1] 公司财务信息 - 公司计划于2025年10月30日报告2025年第三季度财务业绩，并在当天上午7:00举行电话会议 [2] 公司业务与产品管线 - 公司致力于开发治疗阿片类药物使用障碍的药物，其愿景是让所有患者都能获得基于证据的OUD治疗，并将OUD从人类危机转变为可识别和治疗的慢性疾病 [1] - 公司在OUD治疗产品组合的基础上，拥有旨在扩展该类治疗的产品候选管线 [1] 临床研究进展 - 公司本周在JAMA Network Open上发表了一项多中心、开放标签临床试验的结果，该证据支持快速SUBLOCADE®诱导作为改善阿片类药物使用障碍治疗保留率的策略 [3]

Indivior , said on Wednesday it plans to relocate its corporate domicile from the UK to the United States, establishing a new Delaware-based parent company, just months after the pharmaceutical firm m... ...

Accessibility StatementSkip Navigation RICHMOND, Va., Oct. 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it intends to pursue a change in domicile from the U.K. to the U.S. and will establish a new U.S. parent company, Indivior Pharmaceuticals, Inc. (IPI), above its existing U.K. parent company. This follows Indivior's U.S. listing on the Nasdaq Stock Exchange ("Nasdaq") in June 2023 and subsequent cancellation of its secondary listing on the Lon ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Indivior PLC is one of them. Indivior PLC (NASDAQ:INDV) is a pharmaceutical company specializing in treatments for opioid use disorder (OUD), with its core products SUBLOCADE, a once-monthly buprenorphine injection, and SUBOXONE film forming the backbone of its revenue. In September 2025, the corporation reported strong Q2 results, with total net revenue of $302 million. SUBLOCADE sales rose 9% year-over-year to $20 ...

公司业务与市场定位 - 专注于开发治疗成瘾症及其他严重精神健康障碍药物 [1] - 核心业务聚焦于阿片类药物成瘾治疗领域 该领域属于重要公共卫生议题 [1] - 主要竞争对手包括Alkermes和Purdue Pharma等同样专注于成瘾治疗领域的公司 [1] 股价表现与投资潜力 - 目标价格设定为34美元 隐含42.65%的上涨潜力 [2][4][5] - 过去一个月股价上涨3.77% 显示积极趋势 [2][5] - 最近10个交易日微跌0.19% 可能提供更优买入机会 [2][4] 财务状况评估 - 皮奥特罗斯基得分达到8分（总分9分） 反映公司财务实力强劲 [3][5] - 高分数表明公司基本面稳固 对价值型投资者具备特殊吸引力 [3][5]

Indivior (INDV) moved up 11 positions on Monday into the 46th spot on Barchart’s Top 100 Stocks to Buy. The opioid-treatment pharmaceutical company was one of only eight stocks in the top 50 to gain at least 10 spots in yesterday’s trading. The Barchart Technical Opinion is a Strong Buy. Up nearly 13% in the past month and 139% over the past 12 months, momentum is definitely on its side. More News from Barchart UK-based consumer products company Reckitt Benckiser (RBGLY) spun off Indivior in December 20 ...

PresentationThibault BoutherinEquity Analyst I think we start. Good morning, everyone. Thank you for joining this session of the Morgan Stanley Global Healthcare Conference. I'm Thibault Boutherin, I co-head the European Pharm Equity Research team based in London. Before we start, I would like to refer to some important disclosures, which can be found on the Morgan Stanley website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales represent ...

Indivior (NasdaqGS:INDV) FY Conference September 08, 2025 09:15 AM ET Company ParticipantsJoe Ciaffoni - CEO & DirectorThibault Boutherin - Executive Director - Equity ResearchRyan Preblick - CFOThibault BoutherinFingers crossed. Good morning, everyone. Thank you for joining this session of the Morgan Stanley Global Healthcare Conference. I'm Thibault Bouterin. I co-head the European Pharma Equity Research Team based in London. Before we start, I would like to refer to some important disclosures which can b ...

公司活动安排 - 公司首席执行官Joe Ciaffoni与首席财务官Ryan Preblick将于9月8日参加摩根士丹利第23届全球医疗健康大会的一对一/小组会议及炉边讨论[1] - 公司首席执行官与首席财务官将于9月9日参加H C Wainwright第27届全球投资大会的一对一/小组会议[2] - 摩根士丹利会议炉边讨论将于9月8日美东时间上午9:15公开进行 可通过指定网络链接观看[1] 公司业务概况 - 公司专注于开发治疗阿片类药物使用障碍(OUD)的药物 致力于将OUD从全球人类危机转化为可治疗的慢性疾病[3] - 公司在全球30多个国家提供产品 全球员工超过1000人[3] - 公司在现有OUD治疗产品组合基础上 拥有旨在扩展该领域优势的候选产品管线[3]

公司业务定位 - 公司重新成为基于科学的长效注射疗法治疗阿片类药物使用障碍领域的专家[1] 财务表现 - 2025年第二季度业绩表现强劲 包括SUBLOCADE产品线强劲增长和现金流持续改善[1] 研究覆盖范围 - 研究主要聚焦于中小市值公司 这些公司通常被多数投资者忽视[1] - 偶尔也会研究大市值公司 以提供更全面的股票市场视角[1]